Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567383516> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2567383516 endingPage "228" @default.
- W2567383516 startingPage "227" @default.
- W2567383516 abstract "Since the 1980s, platinum-doublet chemotherapy has been the standard of care for first-line therapy in advanced non-small-cell lung cancer without oncogenic drivers, which means in about 85% of white patients. 1 Schiller JH Harrington D Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98 Crossref PubMed Scopus (4797) Google Scholar However, the benefit of such treatment is limited, with a median overall survival between 8 months and 12 months depending on the patient's Eastern Cooperative Oncology Group (ECOG) performance status and the possibility of adjunctive treatment with bevacizumab and of maintenance therapy. Docetaxel (or pemetrexed, if not previously used) is the treatment of choice after first-line progression, with a median survival of around 8 months, at the cost of substantial toxicities. 2 Hanna N Shepherd FA Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1597 Crossref PubMed Scopus (2291) Google Scholar Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialTo our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology, with a favourable safety profile. Full-Text PDF" @default.
- W2567383516 created "2017-01-06" @default.
- W2567383516 creator A5008724268 @default.
- W2567383516 creator A5079143102 @default.
- W2567383516 date "2017-01-01" @default.
- W2567383516 modified "2023-09-27" @default.
- W2567383516 title "Programmed death of chemotherapy in non-small-cell lung cancer?" @default.
- W2567383516 cites W2037139573 @default.
- W2567383516 cites W2104347254 @default.
- W2567383516 cites W2122495232 @default.
- W2567383516 cites W2134667653 @default.
- W2567383516 cites W2156353875 @default.
- W2567383516 cites W2198093519 @default.
- W2567383516 cites W2293531514 @default.
- W2567383516 cites W2296947286 @default.
- W2567383516 cites W2527905628 @default.
- W2567383516 doi "https://doi.org/10.1016/s0140-6736(16)32535-1" @default.
- W2567383516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27979385" @default.
- W2567383516 hasPublicationYear "2017" @default.
- W2567383516 type Work @default.
- W2567383516 sameAs 2567383516 @default.
- W2567383516 citedByCount "5" @default.
- W2567383516 countsByYear W25673835162017 @default.
- W2567383516 countsByYear W25673835162018 @default.
- W2567383516 countsByYear W25673835162020 @default.
- W2567383516 crossrefType "journal-article" @default.
- W2567383516 hasAuthorship W2567383516A5008724268 @default.
- W2567383516 hasAuthorship W2567383516A5079143102 @default.
- W2567383516 hasConcept C121608353 @default.
- W2567383516 hasConcept C126322002 @default.
- W2567383516 hasConcept C141071460 @default.
- W2567383516 hasConcept C143998085 @default.
- W2567383516 hasConcept C2775949291 @default.
- W2567383516 hasConcept C2776256026 @default.
- W2567383516 hasConcept C2776694085 @default.
- W2567383516 hasConcept C2777240266 @default.
- W2567383516 hasConcept C2777701055 @default.
- W2567383516 hasConcept C2777802072 @default.
- W2567383516 hasConcept C2778239845 @default.
- W2567383516 hasConcept C2780030458 @default.
- W2567383516 hasConcept C2781190966 @default.
- W2567383516 hasConcept C2781451048 @default.
- W2567383516 hasConcept C71924100 @default.
- W2567383516 hasConceptScore W2567383516C121608353 @default.
- W2567383516 hasConceptScore W2567383516C126322002 @default.
- W2567383516 hasConceptScore W2567383516C141071460 @default.
- W2567383516 hasConceptScore W2567383516C143998085 @default.
- W2567383516 hasConceptScore W2567383516C2775949291 @default.
- W2567383516 hasConceptScore W2567383516C2776256026 @default.
- W2567383516 hasConceptScore W2567383516C2776694085 @default.
- W2567383516 hasConceptScore W2567383516C2777240266 @default.
- W2567383516 hasConceptScore W2567383516C2777701055 @default.
- W2567383516 hasConceptScore W2567383516C2777802072 @default.
- W2567383516 hasConceptScore W2567383516C2778239845 @default.
- W2567383516 hasConceptScore W2567383516C2780030458 @default.
- W2567383516 hasConceptScore W2567383516C2781190966 @default.
- W2567383516 hasConceptScore W2567383516C2781451048 @default.
- W2567383516 hasConceptScore W2567383516C71924100 @default.
- W2567383516 hasIssue "10066" @default.
- W2567383516 hasLocation W25673835161 @default.
- W2567383516 hasLocation W25673835162 @default.
- W2567383516 hasOpenAccess W2567383516 @default.
- W2567383516 hasPrimaryLocation W25673835161 @default.
- W2567383516 hasRelatedWork W2167650070 @default.
- W2567383516 hasRelatedWork W2754651043 @default.
- W2567383516 hasRelatedWork W2774698410 @default.
- W2567383516 hasRelatedWork W2981916319 @default.
- W2567383516 hasRelatedWork W3016013995 @default.
- W2567383516 hasRelatedWork W3029430426 @default.
- W2567383516 hasRelatedWork W3109173174 @default.
- W2567383516 hasRelatedWork W3186228900 @default.
- W2567383516 hasRelatedWork W4235522950 @default.
- W2567383516 hasRelatedWork W4376109856 @default.
- W2567383516 hasVolume "389" @default.
- W2567383516 isParatext "false" @default.
- W2567383516 isRetracted "false" @default.
- W2567383516 magId "2567383516" @default.
- W2567383516 workType "article" @default.